Arbutus Biopharma Corporation (ABUS): Price and Financial Metrics


Arbutus Biopharma Corporation (ABUS)

Today's Latest Price: $2.04 USD

0.02 (-0.97%)

Updated Jun 4 4:00pm

Add ABUS to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 336 in Biotech

See all "A" rated Strong Buy stocks

ABUS Stock Summary

  • Of note is the ratio of Arbutus Biopharma Corp's sales and general administrative expense to its total operating expenses; merely 5.73% of US stocks have a lower such ratio.
  • The ratio of debt to operating expenses for Arbutus Biopharma Corp is higher than it is for about merely 6.34% of US stocks.
  • With a price/sales ratio of 20.82, Arbutus Biopharma Corp has a higher such ratio than 93.48% of stocks in our set.
  • If you're looking for stocks that are quantitatively similar to Arbutus Biopharma Corp, a group of peers worth examining would be CMRX, ONCT, MUX, MTSI, and RBBN.
  • ABUS's SEC filings can be seen here. And to visit Arbutus Biopharma Corp's official web site, go to www.arbutusbio.com.
ABUS Daily Price Range
ABUS 52-Week Price Range

ABUS Stock Price Chart More Charts


ABUS Price/Volume Stats

Current price $2.04 52-week high $3.66
Prev. close $2.06 52-week low $0.82
Day low $2.01 Volume 2,108,117
Day high $2.18 Avg. volume 967,606
50-day MA $1.52 Dividend yield N/A
200-day MA $1.92 Market Cap 140.68M

Arbutus Biopharma Corporation (ABUS) Company Bio


Arbutus Biopharma Corporation, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of chronic hepatitis B (HBV) infections in Canada and the United States. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. The company is based in Burnaby, Canada.


ABUS Latest News Stream


Event/TimeNews Detail
Loading, please wait...

ABUS Latest Social Stream


Loading social stream, please wait...

View Full ABUS Social Stream

Latest ABUS News From Around the Web

Below are the latest news stories about Arbutus Biopharma Corp that investors may wish to consider to help them evaluate ABUS as an investment opportunity.

Arbutus to Present at Jefferies Virtual Healthcare Conference

WARMINSTER, Pa., May 27, 2020 -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company focused on developing a cure for people with chronic.

Yahoo | May 27, 2020

Biotech Stock Roundup: MRNA, DVAX Up on Coronavirus Treatment Updates, & More

The biotech sector remains in focus with pipeline updates on coronavirus treatments.

Yahoo | May 20, 2020

P/E Ratio Insights for Arbutus Biopharma

In the current session, Arbutus Biopharma Inc. (NASDAQ: ABUS) is trading at $2.43, after a 29.79% increase. Over the past month, the stock increased by 103.10%, and in the past year, by 16.12%. With performance like this, long-term shareholders optimistic but others are more likely to look into the price-to-earnings ratio to see if the stock might be overvalued.Assuming that all other factors are held constant, this could present itself as an opportunity for shareholders trying to capitalize on the higher share price. The stock is currently under from its 52 week high by 33.69%.The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E indicates that shareholders do...

Yahoo | May 19, 2020

Arbutus Announces Single-Dose Week 12 Data in Chronic Hepatitis B Subjects with 60 mg AB-729 Demonstrating a Significant and Continuous Reduction in HBsAg

Arbutus Biopharma Corporation (ABUS), a clinical-stage biopharmaceutical company focused on developing a cure for people with chronic hepatitis B virus (HBV) infection, today reports positive follow-up data from a Phase 1a/1b clinical trial (AB-729-001) in chronic HBV subjects on nucleos(t)ide therapy who received a single subcutaneous injection of 60 mg of AB-729, a proprietary GalNAc delivered RNAi compound. At week 12, the 60 mg single-dose achieved equivalent reductions in HBsAg as the 180 mg single-dose.

Yahoo | May 18, 2020

Forecast: Analysts Think Arbutus Biopharma Corporation's (NASDAQ:ABUS) Business Prospects Have Improved Drastically

Celebrations may be in order for Arbutus Biopharma Corporation (NASDAQ:ABUS) shareholders, with the analysts...

Yahoo | May 18, 2020

Read More 'ABUS' Stories Here

ABUS Price Returns

1-mo 43.66%
3-mo -31.31%
6-mo -10.92%
1-year 25.15%
3-year -40.00%
5-year -85.13%
YTD -26.62%
2019 -27.42%
2018 -24.16%
2017 106.12%
2016 -44.94%
2015 -70.63%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.8931 seconds.